Incyte Corp. INCY
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · incyte.com
Incyte Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of medicines for oncology, inflammation, and autoimmune diseases. Its key marketed product, Jakafi (ruxolitinib), is approved for myelofibrosis, polycythemia vera, and acute graft-versus-host disease, and the company also has a growing portfolio of dermatology and oncology treatments.
Key ratios
FreeCashFlowOnSale TTM 0.26
FreeCashFlowOnSale 2025 0.26
FreeCashFlowOnSale 2024 0.06
FreeCashFlowOnSale 2023 0.13
NetIncomeMargin TTM 0.25
NetIncomeMargin 2025 0.25
NetIncomeMargin 2024 0.01
NetIncomeMargin 2023 0.16
ReturnOnAssets TTM 0.14
ReturnOnAssets 2025 0.14
ReturnOnAssets 2024 0.01
ReturnOnAssets 2023 0.07
ReturnOnEquity TTM 0.3
ReturnOnEquity 2025 0.3
ReturnOnEquity 2024 0.01
ReturnOnEquity 2023 0.13
Recent news
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis
2026-06-26 · BioSpace
Incyte gains $246M non-cash boost from CMS deal
2026-06-22 · StockTitan / SEC 8-K